Spanish competition authority CNMC has filed charges against the country’s leading pharmaceuticals, including Pfizer, S.L.U., Janssen-Cilag, S.A., Merck Sharp & Dohme de España S.A., Lilly, S.A., Sanofi-Aventis, S.A. and Novartis Farmacéutica, S.A. over alleged uncompetitive agreements. The companies are suspected of having set up distribution systems geared towards maintaining a double-pricing scheme, as well as agreements between the various laboratories.
The case dates back to a complaint presented by the European Association of Euro Pharmaceutical Companies (EAEPC) in 2007. In 2009 the CNMC’s predecessor, the CNC, decided to dismiss the case, having failed to find any evidence of competition law violations.
The decision by the former regulator was reversed in March 2016, with a resolution reopening the files and urging the CNMC to continue their investigations into the case.
Full Content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Antitrust Regulator Signals Flexibility in Merger Reviews to Boost Economic Growth
Nov 21, 2024 by
CPI
US Supreme Court Declines to Hear Appeal in Google Antitrust Records Dispute
Nov 21, 2024 by
CPI
Matt Gaetz Withdraws from Consideration for US Attorney General Amid Controversy
Nov 21, 2024 by
CPI
Morocco Fines US Pharma Firm Viatris Over Merger Notification Breach
Nov 21, 2024 by
CPI
FCC Chairwoman Rosenworcel Announces Resignation
Nov 21, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI